Multiple Dose Study of TRx0037

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Alzheimer's Disease
Interventions
DRUG

TRx0037

75mg and 100mg tablets used to create doses of 100mg and 175mg. Active placebo 2mg and blank placebo used as comparators.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Quotient Clinical

OTHER

lead

TauRx Therapeutics Ltd

INDUSTRY

NCT01253499 - Multiple Dose Study of TRx0037 | Biotech Hunter | Biotech Hunter